ERBB2 and neoplasm: These clinical efforts over the past two decades applying 89Zr-labeled HER2-targeting PET tracers have demonstrated the potential of these agents for applications in tumor staging, identifying HER2-positive tumors, and evaluating HER2 heterogeneity2.